Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
07 sept. 2023 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
22 août 2023 07h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 août 2023 16h53 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
03 août 2023 07h01 HE
|
Fulcrum Therapeutics, Inc.
― Screening closed for the Phase 3 REACH pivotal trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) ― ― Expect to report topline data for REACH in the fourth quarter of 2024 ― ―...
Fulcrum Therapeutics Appoints Chief Financial Officer
03 août 2023 06h55 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
27 juil. 2023 07h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients...
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
10 juil. 2023 07h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 juil. 2023 17h30 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., July 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)
20 juin 2023 07h00 HE
|
Fulcrum Therapeutics, Inc.
RANDOLPH, Mass. and CAMBRIDGE, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Today on World FSHD Day, the FSHD Society and Fulcrum Therapeutics (Nasdaq: FULC) announce the launch of Project Mercury, a...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 juin 2023 16h54 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...